Bartosz Hudzik/LinkedIn
May 23, 2026, 16:42
Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared his post a post on X, adding:
“HBR has become synonymous with antithrombotic de-escalation.
Yet bleeding risk alone should not determine treatment intensity.
Many AF, MI, PCI patients classified as HBR remain ischemic-risk dominant, underscoring the need for personalized rather than algorithmic therapy.”
Bartosz Hudzik shared a post on X:
“At EuroPCR 2026, we show that many HBR, AF, MI, PCI patients remain ischemic-risk dominant despite high bleeding risk.
In selected patients, triple antithrombotic therapy may still provide net clinical benefit”
Other posts featuring Bartosz Hudzik on Hemostasis Today.
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association
-
Jul 2, 2026, 16:22Shinto Francis Thekkudan: Delegates Visiting our BMT and Hematology Department from Kazhakstan
-
Jul 2, 2026, 16:13William Aird: When Deciding whether an Adult Patient is Anemic, Which Do You Usually Use?
-
Jul 2, 2026, 16:08Supporting Bleeding Disorders Community and Celebrating ASPEH Milestone – WFH
-
Jul 2, 2026, 15:59Raul Santos: Why Does LDL-C Remain Elevated in Many Patients?
-
Jul 2, 2026, 15:16Tim Patel: How Regular Movement Helps Keep Blood Flowing Throughout the Day